Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Lite Strategy, Inc. Director's Dealing 2021

May 5, 2021

34267_dirs_2021-05-05_00a15bd6-09e2-44f9-b40c-f8e2ab7b767b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: MEI Pharma, Inc. (MEIP)
CIK: 0001262104
Period of Report: 2021-04-30

Reporting Person: GHALIE RICHARD G (Chief Medical Officer)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 17123 Direct
Restricted Stock Units 20000 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (Right to Buy) $1.21 2026-03-07 Common Stock (130000) Direct
Stock Option (Right to Buy) $1.38 2026-07-14 Common Stock (25000) Direct
Stock Option (Right to Buy) $2.88 2027-07-07 Common Stock (65000) Direct
Stock Option (Right to Buy) $4.28 2028-07-12 Common Stock (130000) Direct
Stock Option (Right to Buy) $2.52 2029-07-01 Common Stock (150000) Direct
Stock Option (Right to Buy) $3.49 2030-07-02 Common Stock (150000) Direct

Footnotes

F1: 20,000 restricted stock units vest on July 2, 2022.

F2: All options are currently exercisable.

F3: 1/4th of shares vest one-year from July 7, 2017, with the remaining balance of shares vesting in 36 equal amounts over three years.

F4: 1/4th of shares vest one-year from July 12, 2018, with the remaining balance of shares vesting in 36 equal amounts over three years.

F5: 1/4th of shares vest one-year from July 1, 2019, with the remaining balance of shares vesting in 36 equal amounts over three years.

F6: 1/4th of shares vest one-year from July 2, 2020, with the remaining balance of shares vesting in 36 equal amounts over three years.